Fundamental Analysis of ANAVEX LIFE SCIENCES CORP(NASDAQ:AVXL) stock

Fundamental Rating

Taking everything into account, AVXL scores 3 out of 10 in our fundamental rating. AVXL was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVXL as it has an excellent financial health rating, but there are worries on the profitability. AVXL has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AVXL has reported negative net income.

In the past year AVXL has reported a negative cash flow from operations.

AVXL had negative earnings in each of the past 5 years.

AVXL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -29.34%, AVXL is doing good in the industry, outperforming 69.93% of the companies in the same industry.

Looking at the Return On Equity, with a value of -32.00%, AVXL is in the better half of the industry, outperforming 77.94% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-29.34%
ROE	-32%
ROIC	N/A

ROA(3y)-28.55%

ROA(5y)-53.15%

ROE(3y)-30.76%

ROE(5y)-63.68%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AVXL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 43.75 indicates that AVXL is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 43.75, AVXL belongs to the top of the industry, outperforming 97.33% of the companies in the same industry.

AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	43.75

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 12.04 indicates that AVXL has no problem at all paying its short term obligations.

The Current ratio of AVXL (12.04) is better than 85.41% of its industry peers.

A Quick Ratio of 12.04 indicates that AVXL has no problem at all paying its short term obligations.

AVXL's Quick ratio of 12.04 is amongst the best of the industry. AVXL outperforms 85.41% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	12.04
Quick Ratio	12.04

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.33% over the past year.

EPS 1Y (TTM)13.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16.67%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

AVXL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 99.82% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-22.92%

EPS Next 2Y173.54%

EPS Next 3Y167.24%

EPS Next 5Y99.82%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVXL. In the last year negative earnings were reported.

Also next year AVXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

AVXL's earnings are expected to grow with 167.24% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y173.54%

EPS Next 3Y167.24%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

AVXL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (12/24/2024, 7:56:52 PM)

After market: 11 +0.13 (+1.2%)

10.87

-0.31 (-2.77%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)12-23 2024-12-23/bmo

Earnings (Next)02-05 2025-02-05/bmo

Inst Owners31.82%

Inst Owner Change4.27%

Ins Owners3.05%

Ins Owner Change0%

Market Cap921.78M

Analysts82.22

Price Target36.18 (232.84%)

Short Float %23.95%

Short Ratio15.02

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-0.82%

Min EPS beat(2)-15.86%

Max EPS beat(2)14.22%

EPS beat(4)3

Avg EPS beat(4)10.94%

Min EPS beat(4)-15.86%

Max EPS beat(4)25.63%

EPS beat(8)6

Avg EPS beat(8)9.43%

EPS beat(12)8

Avg EPS beat(12)8.46%

EPS beat(16)10

Avg EPS beat(16)8.29%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	7.1
P/tB	7.1
EV/EBITDA	N/A

EPS(TTM)-0.52

EYN/A

EPS(NY)-0.64

Fwd EYN/A

FCF(TTM)-0.35

FCFYN/A

OCF(TTM)-0.35

OCFYN/A

SpS0

BVpS1.53

TBVpS1.53

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.34%
ROE	-32%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-28.55%

ROA(5y)-53.15%

ROE(3y)-30.76%

ROE(5y)-63.68%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	12.04
Quick Ratio	12.04
Altman-Z	43.75

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)13.33%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-16.67%

EPS Next Y-22.92%

EPS Next 2Y173.54%

EPS Next 3Y167.24%

EPS Next 5Y99.82%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y12.31%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-32.53%

EBIT Next 3Y121.52%

EBIT Next 5YN/A

FCF growth 1Y-7.68%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-7.68%

OCF growth 3YN/A

OCF growth 5YN/A

ANAVEX LIFE SCIENCES CORP (AVXL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens